Literature DB >> 26160862

Unlocking the Potential of High-Throughput Drug Combination Assays Using Acoustic Dispensing.

Grace Ka Yan Chan1, Stacy Wilson2, Stephen Schmidt1, John G Moffat3.   

Abstract

Assessment of synergistic effects of drug combinations in vitro is a critical part of anticancer drug research. However, the complexities of dosing and analyzing two drugs over the appropriate range of doses have generally led to compromises in experimental design that restrict the quality and robustness of the data. In particular, the use of a single dose response of combined drugs, rather than a full two-way matrix of varying doses, has predominated in higher-throughput studies. Acoustic dispensing unlocks the potential of high-throughput dose matrix analysis. We have developed acoustic dispensing protocols that enable compound synergy assays in a 384-well format. This experimental design is considerably more efficient and flexible with respect to time, reagent usage, and labware than is achievable using traditional serial-dilution approaches. Data analysis tools integrated in Genedata Screener were used to efficiently deconvolute the combination compound mapping scheme and calculate compound potency and synergy metrics. We have applied this workflow to evaluate interactions among drugs targeting different nodes of the mitogen-activated protein kinase pathway in a panel of cancer cell lines.
© 2015 Society for Laboratory Automation and Screening.

Entities:  

Keywords:  HTS; acoustic droplet ejection; automated biology; high-throughput screening; informatics and software; screening data analysis

Mesh:

Substances:

Year:  2015        PMID: 26160862     DOI: 10.1177/2211068215593759

Source DB:  PubMed          Journal:  J Lab Autom        ISSN: 2211-0682


  4 in total

1.  Automated Acoustic Dispensing for the Serial Dilution of Peptide Agonists in Potency Determination Assays.

Authors:  Jacqueline Naylor; Alessandra Rossi; Christopher Brankin; David C Hornigold
Journal:  J Vis Exp       Date:  2016-11-10       Impact factor: 1.355

2.  Joining forces: Leveraging novel combination therapies to combat infections with eukaryotic pathogens.

Authors:  Rachel E Ham; Lesly A Temesvari
Journal:  PLoS Pathog       Date:  2020-12-31       Impact factor: 6.823

3.  Unbiased High-Throughput Drug Combination Pilot Screening Identifies Synergistic Drug Combinations Effective against Patient-Derived and Drug-Resistant Melanoma Cell Lines.

Authors:  David A Close; John M Kirkwood; Ronald J Fecek; Walter J Storkus; Paul A Johnston
Journal:  SLAS Discov       Date:  2020-11-18       Impact factor: 3.341

4.  Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors.

Authors:  Mark Merchant; John Moffat; Gabriele Schaefer; Jocelyn Chan; Xi Wang; Christine Orr; Jason Cheng; Thomas Hunsaker; Lily Shao; Stephanie J Wang; Marie-Claire Wagle; Eva Lin; Peter M Haverty; Sheerin Shahidi-Latham; Hai Ngu; Margaret Solon; Jeffrey Eastham-Anderson; Hartmut Koeppen; Shih-Min A Huang; Jacob Schwarz; Marcia Belvin; Daniel Kirouac; Melissa R Junttila
Journal:  PLoS One       Date:  2017-10-05       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.